Cannara Biotech logo

Cannara Biotech(TSX) LOVE

Market CapCA$205.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-32%
5 Year+39%
1 Year+18%
1 Month+6%
CA$2.11
+1.44%
+0.03Today
Cannara Biotech last closing stock price
MetricPriceDate
Last closeCAD 2.082026-10-09
Cannara Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.8%CAD 2.142026-10-02
1 month+6.12%CAD 1.962026-09-09
3 month+14.29%CAD 1.822026-07-10
Year to date+19.54%CAD 1.742025-12-31
1 year+18.18%CAD 1.762025-10-09
3 year+121.28%CAD 0.942023-10-10
5 year+38.67%CAD 1.502021-10-08
Since inception-31.8%CAD 3.052019-01-14

Cannara Biotech Financials at a Glance

Market Cap

CA$205.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$117.76M

Net Income (TTM)

CA$10.86M

EPS (TTM)

CA$0.11

P/E Ratio

18.31

Dividend

CA$0.00

Beta (Volatility)

0.47 (Low)

Price

CA$2.11

Volume

19,243

Open

CA$2.14

Previous Close

CA$2.11

Daily Range

CA$2.08 - CA$2.14

52-Week Range

CA$1.55 - CA$2.37

Estimated Earnings Date

Nov 23, 2026

LOVE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cannara Biotech

Cannara Biotech Inc. specializes in the indoor cultivation, processing, and commercialization of cannabis and its derivative products across Canada. Established in 2017, the company also supplies hemp-derived CBD items through its online retail platform, positioning itself as a key player in the growing cannabis industry.

Products and Services
  • Indoor cultivation of cannabis and derivative products
  • Processing and commercialization of cannabis products
  • Online retail platform for hemp-derived CBD items
Growth Outlook
  • Revenue increased to CAD 27.2 million in Q2 2026
  • Gross profit margin improved to 42.9% in the latest quarter
  • Strong cash flow from operations of CAD 2.9 million in Q2 2026
Financial Highlights
  • Net income of CAD 1.7 million reported in Q2 2026
  • Current ratio of 3.0 indicates strong liquidity position
  • Trailing twelve months (TTM) revenue of CAD 113.4 million
Cannara Biotech Inc. has demonstrated significant growth potential within the cannabis sector, highlighted by its recent revenue figures and improving profit margins. The company’s focus on indoor cultivation and processing allows for high-quality product offerings, catering to the increasing demand for cannabis and CBD products. The strong liquidity position, as indicated by a current ratio of 3.0, provides a solid foundation for future expansion and operational stability. With a TTM revenue of CAD 113.4 million, Cannara Biotech Inc. is well-positioned to capitalize on the evolving market landscape.
AI Generated • Oct 1, 2026

Industry

Personal Products

Sector

Consumer Staples

Employees

452

CEO

Zohar Krivorot

Website

www.cannara.ca

Headquarters

Saint-Laurent, QC H4N 3M9, CA

LOVE Financials

Key Financial Metrics (TTM)

Gross Margin

26.30%

Operating Margin

0.10%

Net Income Margin

9.22%

Return on Equity

9.45%

Return on Capital

15.44%

Return on Assets

5.58%

Earnings Yield

5.46%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$205.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

98.78M

Volume

19.24K

Avg. Volume

48.41K

Financials (TTM)

Gross Profit

CA$30.97M

Operating Income

CA$119.00K

EBITDA

CA$15.38M

Operating Cash Flow

CA$18.46M

Capital Expenditure

-CA$13.72M

Free Cash Flow

CA$4.74M

Cash & ST Invst.

CA$21.81M

Total Debt

CA$37.00M

Cannara Biotech Performance Analysis

Cannara Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-08-31CAD 35,841,386N/A
20232023-08-31CAD 57,260,19359.8%
20242024-08-31CAD 81,747,55142.8%
20252025-08-31CAD 107,202,53531.1%
Cannara Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-08-314.8%
Q12025-11-305.2%
Q22026-02-28-9.7%
Q32026-05-3117.1%
Cannara Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-08-31CAD 0.03N/A
20232023-08-31CAD 0.08196.9%
20242024-08-31CAD 0.07-9.5%
20252025-08-31CAD 0.14101.1%
Cannara Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-08-31-19.0%
Q12025-11-30-70.2%
Q22026-02-2856.5%
Q32026-05-31185.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

CA$31.83M

+16.4%

Gross Profit

CA$6.87M

-46.7%

Gross Margin

21.58%

N/A

Market Cap

CA$205.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$454.57K

N/A

Employees

452

N/A

Net Income

CA$4.84M

+16.9%

EBITDA

CA$4.86M

-39.6%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

CA$21.81M

+51.4%

Total Debt

CA$37.00M

-22.1%

Accounts Receivable

CA$18.52M

+31.4%

Inventory

CA$55.63M

+13.6%

Long Term Debt

CA$27.22M

-20.3%

Short Term Debt

CA$9.78M

-26.6%

Return on Assets

5.58%

N/A

Return on Invested Capital

0.07%

N/A

Free Cash Flow

CA$805.11K

-93.1%

Operating Cash Flow

CA$5.21M

-62.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CRDL.TOCardiol Therapeutics Inc.
CA$1.71-3.93%
RX.VBioSyent Inc.
CA$15.97-6.88%
HLS.TOHLS Therapeutics Inc.
CA$4.05-0.98%
XLY.TOAuxly Cannabis Group Inc.
CA$3.28-1.80%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About LOVE

What is the current price of Cannara Biotech?

Cannara Biotech is trading at CA$2.11 per share.

What is the 52-week range for Cannara Biotech?

Over the past 52 weeks, Cannara Biotech has traded between CA$1.55 and CA$2.37.

How much debt does Cannara Biotech have?

As of the most recent reporting period, Cannara Biotech reported total debt of CA$37.00M.

How much cash does Cannara Biotech have on hand?

Cannara Biotech reported CA$21.81M in cash and cash equivalents in its most recent financial results.

What is Cannara Biotech’s dividend yield?

Cannara Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services